Health-Related Quality of Life During Postoperative Chemoradiotherapy with Oral Uracil-Tegafur and Leucovorin in Rectal Cancer Patients

Ozgen Z., Ozden S., Dane F., ATASOY B. M., Akgunt Z., Yumuk P. F., ...Daha Fazla

HEPATO-GASTROENTEROLOGY, cilt.60, sa.123, ss.533-537, 2013 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 123
  • Basım Tarihi: 2013
  • Doi Numarası: 10.5754/hge12792
  • Dergi Adı: HEPATO-GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.533-537
  • Anahtar Kelimeler: Chemoradiotherapy, Concomitant, Health-related quality of life, Rectal cancer, UFT, ADJUVANT THERAPY, PHASE-III, RADIOTHERAPY, FLUOROURACIL, MULTICENTER, QLQ-C30, UFT
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background/Aims: The objective of this study was to report on the quality of life of locally advanced rectal cancer patients that were treated with uracil-tegafur (UFT)/leucovorin (LV)-based concurrent chemoradiotherapy. Methodology: Twenty-five patients were enrolled into this prospective study. Radiotherapy (50.4Gy) was given with concurrent UFT (300mg/m(2)/day) and LV (30mg/day). Turkish versions of EORTC-QLQC30 and EORTC QLQCR38 were applied at the beginning (HROoL-1) and at the end (HRQoL-2) of chemoradiotherapy. Paired samples t-test was used to compare the difference of means for each scale between HRQoL1 and HRQoL2 and p values <0.05 were considered statistically significant. Results: Study compliance was 80.6%. From baseline to the end of chemoradiotherapy, the mean scores of dyspnea (p=0.006) diarrhea (p=0.005) and micturition (p=0.005) increased significantly. Chemotherapy side effects also increased at the end of therapy (p=0.07). Seventy-six percent (76%) of male patients replied to questions related to sexual problems and functions, whereas no female patients replied. Conclusions: Although, diarrhea and micturition are the major problems, quality of life scores indicate that concurrent oral fluoropyrimidine-based chemoradiotherapy is a feasible treatment.